Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Orphan Medical discontinues glucaric acid development

May 24, 1996

Zoledronate effective in Paget's disease patients

May 24, 1996

Ibandronate demonstrates bone-preserving effects in phase II

May 24, 1996

Ortho claims agents for osteoporosis

May 24, 1996

Akzo Nobel claims contraceptive vaccines

May 17, 1996

RPR, Novo Nordisk form global HRT alliance

May 17, 1996

Yamanouchi claims antidiabetic agents

May 17, 1996

rhIL-11 reduces need for platelet transfusions in chemotherapy recipients

May 17, 1996

Positive preliminary results announced for CholestaGel phase IIa study

May 17, 1996

FO-2546F: ACAT inhibitor from Albophoma yamanashiensis

May 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.